{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:21:36Z","timestamp":1782512496886,"version":"3.54.5"},"reference-count":97,"publisher":"Hindawi Limited","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3217,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.01188.x","type":"journal-article","created":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T11:24:25Z","timestamp":1163157865000},"page":"1662-1672","source":"Crossref","is-referenced-by-count":37,"title":["Tigecycline: a new glycylcycline antimicrobial"],"prefix":"10.1155","volume":"60","author":[{"given":"M. L.","family":"TOWNSEND","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W.","family":"POUND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"DREW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2006,11,10]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.amjmed.2006.04.003","article-title":"Antimicrobial stewardship","volume":"119","author":"Fishman","year":"2006","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijid.2004.07.008","article-title":"Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000","volume":"9","author":"Hoban","year":"2005","journal-title":"Int J Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijantimicag.2004.12.001","article-title":"Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin\/clavulanate and 15 other antimicrobial agents","volume":"25","author":"Pottumarthy","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2004.10.009","article-title":"Increasing prevalence of multidrug-resistantStreptococcus pneumoniae in the United States over a 10-year period: Alexander project","volume":"51","author":"Mera","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB5|cit5","first-page":"593","article-title":"Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America initial results from an international surveillance protocol","volume":"2005","author":"Jones","year":"2003","journal-title":"J Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-0711-5-2","article-title":"Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States","volume":"5","author":"Styers","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0732-8893(98)00108-4","article-title":"Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds","volume":"33","author":"Jones","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.7326\/0003-4819-144-5-200603070-00005","article-title":"Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections","volume":"144","author":"King","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1469-0691.2000.00107.x","article-title":"Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs)","volume":"6","author":"Paterson","year":"2000","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 4","key":"10.1111\/j.1742-1241.2006.01188.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1086\/500663","article-title":"Extended-spectrum beta-lactamases and clinical outcomes: current data","volume":"42","author":"Ramphal","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.289.7.885","article-title":"Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use","volume":"289","author":"Neuhauser","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003495-200363040-00002","article-title":"Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment","volume":"63","author":"Rupp","year":"2003","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1086\/380457","article-title":"Antimicrobial resistance trends and outbreak frequency in United States hospitals","volume":"38","author":"Diekema","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1086\/342577","article-title":"Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection","volume":"35","author":"Quale","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1097\/01.CCM.0000087326.59341.51","article-title":"Intensive care unit management of intra-abdominal infection","volume":"31","author":"Marshall","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10096-004-1199-0","article-title":"Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery","volume":"23","author":"Krobot","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl. 5","key":"10.1111\/j.1742-1241.2006.01188.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections","volume":"41","author":"Bradford","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB18|cit18","volume-title":"Tygacil","year":"2006"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","article-title":"The glycylcyclines: a comparative review with the tetracyclines","volume":"64","author":"Zhanel","year":"2004","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0960-894X(99)00216-4","article-title":"Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936","volume":"9","author":"Sum","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"219S","DOI":"10.1592\/phco.20.14.219S.35046","article-title":"Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent","volume":"20","author":"Projan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB24|cit24","volume-title":"In Vitro Pharmacodynamics and Post-Antibiotic Effects (PAE) of Tigecycline Against Gram-Negative Bacteria","author":"Reese","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.44.4.1085-1088.2000","article-title":"Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci","volume":"44","author":"Hoellman","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria","volume":"44","author":"Van Ogtrop","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB27|cit27","volume-title":"Activity of Daptomycin and Tigecycline Against Clinical Isolates Causing Catheter-Related Methicillin-Resistant Staphylococcus aureus (CR-MRSA) Embedded in Biofilm","author":"Hachem","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/jac\/35.4.449","article-title":"Glycylcyclines: a new generation of tetracyclines","volume":"35","author":"Tally","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/mdr.2000.6.277","article-title":"Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines","volume":"6","author":"Tuckman","year":"2000","journal-title":"Microb Drug Resist"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1128\/AAC.38.7.1658","article-title":"Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines","volume":"38","author":"Rasmussen","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/AAC.39.9.1948","article-title":"Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa","volume":"39","author":"Li","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2958.1996.281397.x","article-title":"Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa","volume":"21","author":"Poole","year":"1996","journal-title":"Mol Microbiol"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2958.1997.2281594.x","article-title":"Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa","volume":"23","author":"Kohler","year":"1997","journal-title":"Mol Microbiol"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1128\/AAC.43.11.2624","article-title":"Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides","volume":"43","author":"Aires","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/AAC.43.2.415","article-title":"Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa","volume":"43","author":"Mine","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1128\/AAC.43.12.2975","article-title":"Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability","volume":"43","author":"Westbrock-Wadman","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1128\/AAC.48.6.2179-2184.2004","article-title":"Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936)","volume":"48","author":"Hirata","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/AAC.49.3.1017-1022.2005","article-title":"Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.49.2.791-793.2005","article-title":"AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/AAC.47.2.665-669.2003","article-title":"AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis","volume":"47","author":"Visalli","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB42|cit42","volume-title":"E.\u00a0coli Clinical Isolates with Decreased Tigecycline (TGC) Susceptibility Exhibit Altered Expression of MarA, AcrAB and Other Genes","author":"Keeney","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB43|cit43","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically","author":"Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]","year":"2003"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB44|cit44","volume-title":"Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests","author":"Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]","year":"2003"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB45|cit45","volume-title":"Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria","author":"Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB46|cit46","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing - 15th Informational Supplement","author":"Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB47|cit47","unstructured":"Tygacil EMEA Product Information 2006 http:\/\/www.emea.eu.int\/humandocs\/PDFs\/EPAR\/tygacil\/H-644-PI-en-pdf"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1128\/AAC.49.8.3325-3333.2005","article-title":"Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents","volume":"49","author":"Bogdanovich","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center","volume":"52","author":"Bozdogan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jhin.2006.02.011","article-title":"Staphylococcus aureus bacteraemia: incidence, risk factors and predictors for death in a Brazilian teaching hospital","volume":"63","author":"Guilarde","year":"2006","journal-title":"J Hosp Infect"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB51|cit51","volume-title":"Tigecycline Is Highly Active Against 2084 Bacteremic Streptococcus pneumoniae in Canada (2002-2004)","author":"Hoban","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","article-title":"In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)","volume":"52","author":"Hoban","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2005.06.004","article-title":"In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)","volume":"52","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diagmicrobio.2004.11.006","article-title":"In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002","volume":"51","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0732-8893(01)00269-3","article-title":"In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases","volume":"40","author":"Biedenbach","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB56|cit56","volume-title":"Activity of Tigecycline Against ESBL and AmpC Hyperproducing Enterobacteriaceae","author":"Hope","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/mdr.2005.11.330","article-title":"In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan","volume":"11","author":"Cheng","year":"2005","journal-title":"Microb Drug Resist"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","article-title":"Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.47.2.533-540.2003","article-title":"Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia","volume":"47","author":"Edelstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0924-8579(00)00198-9","article-title":"In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis","volume":"16","author":"Roblin","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.45.9.2604-2608.2001","article-title":"Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones","volume":"45","author":"Kenny","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/AAC.46.10.3164-3167.2002","article-title":"Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria","volume":"46","author":"Wallace","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0732-8893(00)00193-0","article-title":"In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae","volume":"38","author":"Patel","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dki477","article-title":"In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis","volume":"57","author":"Petersen","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.50.4.1298-1303.2006","article-title":"Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model","volume":"50","author":"LaPlante","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB66|cit66","volume-title":"Tigecycline Phamacokinetics (data on file)","year":"2006"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","article-title":"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients","volume":"26","author":"Postier","year":"2004","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB69|cit69","volume-title":"Tissue Distribution of GAR-936, A Broad Spectrum Antibiotic in Male Rats","author":"Tombs","year":"1999"},{"issue":"2 Suppl.","key":"10.1111\/j.1742-1241.2006.01188.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clpt.2005.01.005","article-title":"An open-label clinical evaluation of tigecycline concentrations in selected tissues and fluids","volume":"77","author":"Gotfried","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.49.4.1629-1632.2005","article-title":"Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations","volume":"49","author":"Sun","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB73|cit73","volume-title":"Tigeycline (TGC) Concentration (Cp) in Lung Tissue, Cerebrospinal Fluid (CSF) , and Bile of Human Subjects","author":"Rodvold","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB74|cit74","volume-title":"Metabolic Disposition (14C) Tigecycline in Human Volunteers Following Intravenous Infusion","author":"Hoffmann","year":"2004"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2006.01188.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1179\/joc.2005.17.Supplement-1.12","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline","volume":"17","author":"Rello","year":"2005","journal-title":"J Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB76|cit76","volume-title":"The Effects of Renal Disease on the Pharmacokinetics of Tigecycline (GAR-936)","author":"Troy","year":"2003"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB77|cit77","volume-title":"Pharmacokinetics of Tigecycline (TGC) in Patients with Hepatic Impairment","author":"Saunders","year":"2005"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2005.05.006","article-title":"Pharmacokinetic\/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent","volume":"52","author":"Meagher","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.49.4.1656-1659.2005","article-title":"Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB80|cit80","volume-title":"Tigecycline and Digoxin Co-Administered to Healthy Men","author":"Zimmerman","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind Phase 3 comparison study with vancomycin-aztreonam","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijid.2005.05.003","article-title":"Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a Phase 3, randomized, double-blind trial","volume":"9","author":"Sacchidanand","year":"2005","journal-title":"Int J Infect Dis"},{"issue":"Suppl. 5","key":"10.1111\/j.1742-1241.2006.01188.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijsu.2005.03.011","article-title":"Gradauskas Aeal. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections","volume":"3","author":"Fomin","year":"2005","journal-title":"Int J Surg"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline vs. imipenem\/cilastatin in patients with complicated intra-abdominal infections","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"issue":"Suppl. 5","key":"10.1111\/j.1742-1241.2006.01188.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1128\/AAC.44.11.3022-3027.2000","article-title":"Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis","volume":"44","author":"Murphy","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dki109","article-title":"Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model","volume":"55","author":"Yin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.47.1.216-222.2003","article-title":"Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis","volume":"47","author":"Lefort","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB90|cit90","volume-title":"Redbook: Pharmacy's Fundamental Reference","author":"Flemming","year":"2006"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diagmicrobio.2005.06.011","article-title":"Antimicrobial activity and pharmacokinetics\/pharmacodynamics of the novel glycylcycline, tigecycline","volume":"52","author":"Peterson","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2005.05.005","article-title":"Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004)","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1590\/S1413-86702005000500001","article-title":"In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America","volume":"9","author":"Gales","year":"2005","journal-title":"Braz J Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB95|cit95","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2005.06.010","article-title":"Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB96|cit96","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.48.3.1034-1036.2004","article-title":"In vitro activities of tigecycline against the Bacteroides fragilis group","volume":"48","author":"Jacobus","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2006.01188.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.01188.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.01188.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:41Z","timestamp":1643349881000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.01188.x"}},"subtitle":["TIGECYCLINE REVIEW"],"short-title":[],"issued":{"date-parts":[[2006,11,10]]},"references-count":97,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01188.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11,10]]}}}